Blast Percentage in Peripheral Blood

Defining Normal vs. Pathologic Blast Counts

Healthy individuals have less than 1% blasts in peripheral blood, with most normal peripheral smears showing 0% blasts, according to the World Health Organization classification 1, 2
The World Health Organization explicitly states that normal individuals should have fewer than 1% blasts in the peripheral blood 1, 2
Complete remission criteria for acute myeloid leukemia require absence of circulating blasts in peripheral blood, as defined by the American Society of Hematology 3

2-4% peripheral blood blasts is sufficient to diagnose refractory anemia with excess blasts-1 (RAEB-1), reflecting the prognostic significance of circulating blasts, as stated by the International Working Group for Myelodysplastic Syndromes 1, 2
5-19% peripheral blood blasts classifies as RAEB-2, the highest grade of MDS before transformation to acute leukemia, according to the World Health Organization classification 1, 2
≥20% peripheral blood blasts meets diagnostic criteria for acute myeloid leukemia, as defined by the National Comprehensive Cancer Network 3

A minimum 500-cell differential count is essential for reliable blast percentage determination, as recommended by the European Hematology Association 4
With a 500-cell differential, the confidence interval for a reported 5% blast count narrows to 3.3-7.3%, providing much greater diagnostic precision, according to the International Society for Laboratory Hematology 4

Normal leukocyte differential in complete remission requires disappearance of nucleated red blood cells, blasts, and immature myeloid cells in the peripheral smear, as defined by the European LeukemiaNet 5, 6

Patients with 2-4% blasts in peripheral blood and <5% in bone marrow should be diagnosed as refractory anemia with excess blasts-1 (RAEB-1) if other clinical and laboratory findings of myelodysplastic syndrome are present, according to the National Comprehensive Cancer Network 7
A blast count of 10-19% in bone marrow or peripheral blood is used to define accelerated phase in myeloid neoplasms, similar to chronic myeloid leukemia, as recommended by the National Comprehensive Cancer Network 8, 9
A threshold of ≥20% blasts in peripheral blood meets the diagnostic criteria for acute myeloid leukemia (AML) according to the National Comprehensive Cancer Network and the World Health Organization 10
The blast phase is defined as ≥20% blasts in bone marrow and/or peripheral blood, which can present as AML, acute lymphoblastic leukemia (ALL), or mixed-lineage acute leukemia, as stated by the National Comprehensive Cancer Network 8, 9

Blasts are identified by a fine chromatin pattern, prominent nucleoli, a high nuclear‑to‑cytoplasmic ratio, and immature cytoplasm on peripheral blood smear microscopy. 11

Hemodilution can falsely lower the reported peripheral blood blast percentage, especially in patients with fatty or fibrotic bone marrow. 11

When a patient presents with unexplained cytopenias, a manual microscopic review of the peripheral blood smear should be performed to detect possible blasts. 11

Detection of any blasts in the peripheral blood smear—even when the blast count is below 1%—should prompt immediate bone‑marrow aspiration and biopsy with comprehensive ancillary studies (flow cytometry, cytogenetics, molecular testing) for accurate quantification and treatment planning. 11

Achieving complete remission requires a peripheral blood blast count of 0%. [12][13]14

A peripheral blood blast proportion of ≥ 20% fulfills the diagnostic criteria for acute myeloid leukemia. 15